KYVERNA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.38 USD | +5.09% |
|
+12.60% | 0.00% |
| Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
| Mar. 26 | Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 630.8 | - | - |
| Enterprise Value (EV) 1 | 434.2 | 489.1 | 425.3 |
| P/E ratio | -4.6 x | -3.7 x | -3.24 x |
| Yield | - | - | - |
| Capitalization / Revenue | 168 x | 126 x | 75.7 x |
| EV / Revenue | 116 x | 97.8 x | 51 x |
| EV / EBITDA | -3.41 x | -2.48 x | -2.01 x |
| EV / FCF | -3.59 x | -2.62 x | - |
| FCF Yield | -27.9% | -38.2% | - |
| Price to Book | 5.81 x | -7.99 x | 113 x |
| Nbr of stocks (in thousands) | 43,115 | - | - |
| Reference price 2 | 14.63 | 14.63 | 14.63 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | 3.75 | 5 | 8.333 |
| EBITDA 1 | - | -60.7 | -127.2 | -197.5 | -211.7 |
| EBIT 1 | - | -62.41 | -141 | -199.6 | -211.1 |
| Operating Margin | - | - | -3,759.15% | -3,991.87% | -2,532.61% |
| Earnings before Tax (EBT) 1 | - | -60.37 | -129.8 | -189.6 | -217.1 |
| Net income 1 | -28.89 | -60.37 | -129.8 | -198.5 | -217.1 |
| Net margin | - | - | -3,460.8% | -3,970.07% | -2,605.22% |
| EPS 2 | -13.94 | -89.61 | -3.180 | -3.956 | -4.510 |
| Free Cash Flow 1 | - | -53.03 | -121 | -187 | - |
| FCF margin | - | - | -3,226.67% | -3,740% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 10/5/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | -20.92 | - | - | - | - |
| EBIT 1 | -21.38 | -32 | -37 | -39 | -42 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS 2 | -75.82 | -0.8000 | -0.7500 | -0.7700 | -0.8600 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/26/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 197 | 142 | 205 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -53 | -121 | -187 | - |
| ROE (net income / shareholders' equity) | - | - | -53.6% | -670% | - |
| ROA (Net income/ Total Assets) | - | - | -47.1% | -44.8% | - |
| Assets 1 | - | - | 275.7 | 443.2 | - |
| Book Value Per Share 2 | - | - | 2.520 | -1.830 | 0.1300 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 0.62 | 7 | 10 | - |
| Capex / Sales | - | - | 186.67% | 200% | - |
| Announcement Date | 10/5/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.63
USD
Average target price
42.75
USD
Spread / Average Target
+192.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 631M | |
| +28.30% | 48.16B | |
| -0.16% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +11.02% | 25.59B | |
| -22.68% | 18.96B | |
| +8.63% | 12.92B | |
| +29.93% | 12.03B | |
| -1.79% | 11.77B |
- Stock Market
- Equities
- KYTX Stock
- Financials Kyverna Therapeutics, Inc.